ATE272625T1 - Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung - Google Patents

Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung

Info

Publication number
ATE272625T1
ATE272625T1 AT99918355T AT99918355T ATE272625T1 AT E272625 T1 ATE272625 T1 AT E272625T1 AT 99918355 T AT99918355 T AT 99918355T AT 99918355 T AT99918355 T AT 99918355T AT E272625 T1 ATE272625 T1 AT E272625T1
Authority
AT
Austria
Prior art keywords
oxyiminoalkaneous
hypoglycemic
acid derivatives
hypolipidemic effects
hypolipidemic
Prior art date
Application number
AT99918355T
Other languages
English (en)
Inventor
Yu Momose
Hiroyuki Odaka
Hiroshi Imoto
Hiroyuki Kimura
Junichi Sakamoto
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE272625T1 publication Critical patent/ATE272625T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
AT99918355T 1998-05-11 1999-05-10 Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung ATE272625T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12792298 1998-05-11
JP12792198 1998-05-11
PCT/JP1999/002407 WO1999058510A1 (en) 1998-05-11 1999-05-10 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

Publications (1)

Publication Number Publication Date
ATE272625T1 true ATE272625T1 (de) 2004-08-15

Family

ID=26463748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99918355T ATE272625T1 (de) 1998-05-11 1999-05-10 Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung

Country Status (26)

Country Link
US (3) US6251926B1 (de)
EP (2) EP1428531A1 (de)
JP (1) JP2000198772A (de)
KR (1) KR100388120B1 (de)
CN (1) CN1148361C (de)
AR (1) AR029876A1 (de)
AT (1) ATE272625T1 (de)
AU (1) AU766831B2 (de)
BR (1) BR9910371A (de)
CA (1) CA2331879A1 (de)
CO (1) CO5040066A1 (de)
DE (1) DE69919156T2 (de)
ES (1) ES2226377T3 (de)
HU (1) HUP0103714A3 (de)
ID (1) ID28699A (de)
IL (1) IL139470A0 (de)
LV (1) LV12606B (de)
MY (1) MY123337A (de)
NO (1) NO317426B1 (de)
NZ (1) NZ508066A (de)
PE (1) PE20000625A1 (de)
PL (1) PL344002A1 (de)
PT (1) PT1077957E (de)
RU (1) RU2213738C2 (de)
SK (1) SK16412000A3 (de)
WO (1) WO1999058510A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY123337A (en) * 1998-05-11 2006-05-31 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives.
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DK1206457T3 (da) * 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
DE19948126A1 (de) * 1999-10-06 2001-04-12 Max Delbrueck Centrum Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock
WO2001032608A1 (en) * 1999-10-29 2001-05-10 Takeda Chemical Industries, Ltd. Process for the preparation of oxyiminoalkanoic acid derivatives
AR031078A1 (es) 1999-10-29 2003-09-10 Takeda Pharmaceutical Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
EP1304121A4 (de) * 1999-11-10 2004-06-23 Takeda Chemical Industries Ltd Inhibitoren der koerpergewichtszunahme
ES2225252T3 (es) 1999-11-10 2005-03-16 Takeda Chemical Industries, Ltd. Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica.
EP1229026A4 (de) * 1999-11-10 2003-09-24 Takeda Chemical Industries Ltd Alkoxyiminoalkansäure-derivate
EP1277730A4 (de) * 2000-03-28 2005-03-16 Hemmer der neovaskularisation
EP1310494B1 (de) * 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. Ppar-delta aktivatoren
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
DE60139025D1 (de) 2000-12-28 2009-07-30 Takeda Pharmaceutical Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
US7241785B2 (en) 2001-03-23 2007-07-10 Takeda Pharmaceutical Company Limited Five-membered heterocyclic alkanoic acid derivative
ATE480236T1 (de) * 2001-04-25 2010-09-15 Takeda Pharmaceutical Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
WO2003059372A2 (en) * 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and a modulator of diabetic late complications
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
US8168233B2 (en) * 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
EP1559422B1 (de) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Mittel zur kontrolle der rezeptorfunktion
AU2003297062A1 (en) * 2002-12-11 2004-06-30 University Of Massachusetts METHOD OF INTRODUCING siRNA INTO ADIPOCYTES
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
ATE551056T1 (de) * 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme
US7625916B2 (en) * 2003-09-17 2009-12-01 Kaname Kawasugi Medicinal composition
US7718704B2 (en) * 2004-02-24 2010-05-18 Irm Llc Immunosuppressant compounds and compositions
BRPI0509305A (pt) * 2004-03-29 2007-09-04 Sankyo Co uso de um sensibilizador insulìnico, composição farmecêutica, e , kit
EP2253315A1 (de) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoylsäure derivaten
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
CN101014332A (zh) * 2004-09-13 2007-08-08 参天制药株式会社 角膜结膜病变治疗剂
US7556933B2 (en) * 2004-10-01 2009-07-07 Luminultra Technologies Ltd. Reagent system and process for adenosine triphosphate monitoring
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
WO2006118320A1 (ja) 2005-04-28 2006-11-09 Takeda Pharmaceutical Company Limited チエノピリミドン化合物
US7781469B2 (en) 2005-05-27 2010-08-24 Shionogi & Co., Ltd. Arylacetate derivatives having isoxazole skeleton
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US7491414B2 (en) * 2005-10-12 2009-02-17 Gaia Herbs, Inc. Anti-inflammatory substances extracted from Echinacea
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
WO2009128481A1 (ja) 2008-04-16 2009-10-22 武田薬品工業株式会社 含窒素５員複素環化合物
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010016552A1 (ja) 2008-08-07 2010-02-11 武田薬品工業株式会社 過敏性腸症候群治療薬
CA2782776A1 (en) 2008-12-04 2010-06-10 Ikfe Gmbh Biomarkers for atherosclerosis
US20110118134A1 (en) 2008-12-11 2011-05-19 Ikfe Gmbh Biomarkers for insulin sensitizer drug response
US20100209350A1 (en) 2008-12-30 2010-08-19 Andreas Pfuetzner Biomarkers for Adipose Tissue Activity
EP2382475A2 (de) 2009-01-07 2011-11-02 IKFE GmbH Biomarker für appetitregulierung
CN102875548A (zh) * 2011-07-14 2013-01-16 中国科学院大连化学物理研究所 一类基于肟的通过[2+2+2]环加成合成吡啶衍生物的方法
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
JP6299591B2 (ja) 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
BR112016007078A2 (pt) 2013-09-30 2017-12-12 Ono Pharmaceutical Co composto tendo atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo
US20160083380A1 (en) * 2013-12-16 2016-03-24 Cadila Healthcare Limited Oximino derivatives for the treatment of dyslipidemia
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
FR3042903B1 (fr) * 2015-10-21 2017-12-08 Commissariat Energie Atomique Utilisation d'acides hydroxyiminoalcanoiques comme agents anti-nitreux dans des operations de desextraction reductrice du plutonium
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
MX2019009419A (es) 2017-02-08 2019-10-02 Ono Pharmaceutical Co Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo.
EP4268676A3 (de) 2019-02-21 2024-02-07 Steelcase Inc. Körperstützanordnung und verfahren zur verwendung und montage davon
US11357329B2 (en) 2019-12-13 2022-06-14 Steelcase Inc. Body support assembly and methods for the use and assembly thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177578B (en) 1976-08-27 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
JPS5849382A (ja) 1981-09-18 1983-03-23 Kyowa Hakko Kogyo Co Ltd β−ラクタム化合物
JPS59167576A (ja) 1983-03-15 1984-09-21 Kyowa Hakko Kogyo Co Ltd β−ラクタム化合物
JPS6277391A (ja) 1984-12-21 1987-04-09 Mochida Pharmaceut Co Ltd セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤
JPS62158290A (ja) * 1985-12-28 1987-07-14 Banyu Pharmaceut Co Ltd 新規セフアロスポリン誘導体
US4698338A (en) * 1986-02-19 1987-10-06 Eli Lilly And Company 7[2-(2-aminothiazol-4-yl)-2-benzyloximino]acetamido-3[4-alkyl-5-oxo-6-hydroxy-3,4-dihydro-1,2,4-triazin-3-yl]thiomethyl cephalosporins
US5750532A (en) * 1986-12-10 1998-05-12 Schering Corporation Pharmaceutically active compounds
JPH0277391A (ja) 1988-09-14 1990-03-16 Suzuki Motor Co Ltd 水ジェット推進船のビルジ水排水装置
EP0370629B2 (de) 1988-11-21 1998-01-07 Zeneca Limited Fungizide
EP0400805A1 (de) 1989-04-25 1990-12-05 Toshiyasu Ishimaru Cephalosporinverbindungen und ihre Verwendung
JPH03115272A (ja) * 1989-10-19 1991-05-16 Banyu Pharmaceut Co Ltd マンデル酸誘導体およびその製法
IL98506A (en) * 1990-06-18 1996-09-12 Fujisawa Pharmaceutical Co Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them
DE59109047D1 (de) * 1990-06-27 1998-10-08 Basf Ag O-Benzyl-Oximether und diese Verbindungen enthaltende Pflanzenschutzmittel
JPH04112890A (ja) * 1990-09-04 1992-04-14 Ajinomoto Co Inc 新規チアゾール誘導体及び該誘導体を含有する抗菌剤
EP0486011A3 (en) * 1990-11-16 1992-07-15 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition against pneumocystis carinii
DE4105551A1 (de) * 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
RU2032677C1 (ru) * 1992-05-05 1995-04-10 Бристоль-Мейерз Сквибб Компани Производные оксазола
JP2691679B2 (ja) 1992-07-21 1997-12-17 小野薬品工業株式会社 オキシム誘導体およびそれを含有する医薬品
US5512581A (en) * 1994-07-18 1996-04-30 Abbott Laboratories Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
US5703096A (en) 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
CH689228A5 (de) 1994-10-07 1998-12-31 Novartis Ag Oximether, sowie diese enthaltende Pflanzenschutzmittel.
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
AU5701896A (en) * 1995-06-02 1996-12-18 Sankyo Company Limited Aromatic oxyimino derivatives
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
FR2737893B1 (fr) * 1995-08-16 1997-09-12 Roussel Uclaf Nouvelles cephalosporines comportant en position 7, un radical benzyloxyimino substitue, leur procede et intermediaires de preparation, leur application comme medicaments
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JPH09323929A (ja) 1996-04-02 1997-12-16 Sankyo Co Ltd オキシム誘導体を含有する医薬
KR20000005224A (ko) 1996-04-04 2000-01-25 가와무라 요시부미 페닐알킬카르복실산 유도체_
AU4050797A (en) 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
ES2320181T3 (es) 1997-07-24 2009-05-19 Astellas Pharma Inc. Composiciones farmaceuticas que tienen un efecto reductor del colesterol.
JPH11193272A (ja) 1997-10-01 1999-07-21 Sankyo Co Ltd フェニルアルキルカルボン酸誘導体を含有する医薬
MY123337A (en) * 1998-05-11 2006-05-31 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives.

Also Published As

Publication number Publication date
WO1999058510A1 (en) 1999-11-18
LV12606B (en) 2001-05-20
MY123337A (en) 2006-05-31
CA2331879A1 (en) 1999-11-18
JP2000198772A (ja) 2000-07-18
US20030186985A1 (en) 2003-10-02
DE69919156T2 (de) 2005-11-03
KR100388120B1 (ko) 2003-06-18
NO20005531L (no) 2001-01-05
CN1148361C (zh) 2004-05-05
LV12606A (lv) 2001-01-20
AR029876A1 (es) 2003-07-23
EP1077957B1 (de) 2004-08-04
PT1077957E (pt) 2004-10-29
HK1034972A1 (en) 2001-11-09
AU766831B2 (en) 2003-10-23
RU2213738C2 (ru) 2003-10-10
NO317426B1 (no) 2004-10-25
HUP0103714A3 (en) 2003-05-28
EP1077957A1 (de) 2001-02-28
BR9910371A (pt) 2001-01-09
SK16412000A3 (sk) 2001-08-06
EP1428531A1 (de) 2004-06-16
DE69919156D1 (de) 2004-09-09
PL344002A1 (en) 2001-09-10
NZ508066A (en) 2003-03-28
ES2226377T3 (es) 2005-03-16
CO5040066A1 (es) 2001-05-29
PE20000625A1 (es) 2000-07-24
ID28699A (id) 2001-06-28
US6251926B1 (en) 2001-06-26
KR20010021523A (ko) 2001-03-15
US6495581B1 (en) 2002-12-17
NO20005531D0 (no) 2000-11-02
AU3629799A (en) 1999-11-29
US6924300B2 (en) 2005-08-02
CN1300285A (zh) 2001-06-20
HUP0103714A2 (hu) 2002-01-28
IL139470A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
DE69919156D1 (de) Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung
ATE271049T1 (de) Fünfgliedrige n-heterocyclen mit hypoglykämischer und hypolipidemischer wirkung
ATE234817T1 (de) Hetaroylcyclohexandionderivate mit herbizider wirkung
DE59907732D1 (de) Kosmetische wirkstoffzubereitung mit hohem radikalschutzfaktor
DE69913233D1 (de) Kosmetische zusammensetzung
DE69931501D1 (de) Kosmetische zusammensetzung
DE69916329D1 (de) Kosmetische formulierung
DE69934805D1 (de) Substituierte imidazole mit cytokin-inhibierender wirkung
DE59708160D1 (de) 1-Dimethylaminomethyl-2-phenyl-cycloalk-2-enverbindungen mit analgetischer Wirkung
DE69904147D1 (de) Juckreizstillende agentien in kosmetische mittel
EE200200341A (et) Asendatud oksasolidinoonid ja nende kasutamine
DE60038268D1 (de) Kosmetische Zubereitungen
DE60025147D1 (de) Kosmetische Zusammensetzung und Verwendungen
DE69831233D1 (de) Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
DE60029454D1 (de) Wässrige kosmetische zusammensetzung mit verbesserter stabilität
ID27776A (id) Bahan dengan efek antidepresan
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
EE200100347A (et) 3,3-biarüülpiperidiini ja 2,2-biarüülmorfoliini derivaadid
DE69524043D1 (de) Carbodiimide Derivate
DE69915215D1 (de) Kosmetische Sonnenschutzmittel
DE59909255D1 (de) Kosmetische zubereitungen
DE69915564D1 (de) Nahe-Infrarot-Absorbtionszusammensetzung
DE69834091D1 (de) Kosmetische Zubereitung
DK1077984T3 (da) 2'-Deoxyhygromycin derivater
DE59508203D1 (de) Substituierte phthalimido-zimtsäurederivate mit herbizider wirkung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1077957

Country of ref document: EP

REN Ceased due to non-payment of the annual fee